>Marché des médicaments contre l'adénomyose en Amérique du Nord, par type (diffus, nodulaire, sclérotique, kystique adulte, autres), traitement (médicaments hormonaux, anti-inflammatoires ), type de patient ( adultegériatrique , adolescent), forme posologique (parentérale, orale, autres), utilisateur final (hôpitaux, cliniques, centres spécialisés, centres ambulatoires, soins à domicile, autres), canal de distribution (pharmacie hospitalière, pharmacie de détail, pharmacie en ligne, autres) - Tendances et prévisions de l'industrie jusqu'en 2029.
Analyse et perspectives du marché
L'adénomyose est une maladie utérine bénigne dans laquelle les glandes endométriales et le stroma sont pathologiquement mis en évidence dans le myomètre. Les femmes touchées par l'adénomyose peuvent présenter des saignements utérins anormaux (SUA), une dysménorrhée, une dyspareunie ou une infertilité, mais un tiers d'entre elles sont asymptomatiques. Au fil des ans, l'adénomyose est restée un diagnostic histopathologique posé après une hystérectomie chez les femmes périménopausées présentant des saignements menstruels abondants (HMB) ou des douleurs pelviennes. Cependant, l'adénomyose est également devenue une affection identifiée chez les jeunes femmes en âge de procréer au cours de la dernière décennie en raison des récents progrès des techniques d'imagerie, même si une définition et une classification communes font encore défaut. Malgré l'amélioration des outils de diagnostic, la connaissance de la maladie reste faible.
Les médicaments utilisés pour le traitement de l'adénomyose comprennent généralement des anti-inflammatoires et des médicaments hormonaux tels que les analogues de l'hormone de libération des gonadotrophines (analogues de la Gnrh), l'œstrogène-progestatif, les modulateurs sélectifs des récepteurs de la progestérone (SPRM) ou la progestérone, les inhibiteurs de l'aromatase et les antagonistes de l'hormone de libération des gonadotrophines, entre autres. Certains de ces médicaments sont utilisés pour réduire la taille des lésions adénomyotiques et améliorer la dysménorrhée et la qualité de vie du patient.
La demande de médicaments contre l'adénomyose a augmenté dans les pays développés. Ces pays ont mis en place des politiques de remboursement du traitement, en raison de la forte prévalence de la maladie et de l'augmentation des dépenses de santé. Le marché va croître au cours de la période prévue en raison de l'exploration des marchés émergents et du soutien croissant des organismes privés et gouvernementaux au traitement.
Le rapport sur le marché des médicaments contre l'adénomyose en Amérique du Nord fournit des détails sur la part de marché, les nouveaux développements, l'impact des acteurs du marché national et local, analyse les opportunités en termes de poches de revenus émergentes, les changements dans la réglementation du marché, les approbations de produits, les décisions stratégiques, les lancements de produits, les expansions géographiques et les innovations technologiques sur le marché. Pour comprendre l'analyse et le scénario du marché, contactez-nous pour un briefing d'analyste. Notre équipe vous aidera à créer une solution d'impact sur les revenus pour atteindre votre objectif souhaité. Les initiatives stratégiques telles que la collaboration, l'accord et la signature d'accords de vente pour inventer et innover dans les traitements pharmacologiques sont les principaux moteurs qui ont propulsé la demande du marché au cours de la période de prévision.
North America adenomyosis drugs market is supportive and aims to reduce the progression of the disease. Data Bridge Market Research analyses that the North America adenomyosis drugs market will grow at a CAGR of 6.4% during the forecast period of 2022 to 2029.
|
Report Metric |
Details |
|
Forecast Period |
2022 to 2029 |
|
Base Year |
2021 |
|
Historic Years |
2020 (Customizable to 2019 - 2014) |
|
Quantitative Units |
Revenue in USD Thousand, Pricing in USD |
|
Segments Covered |
By Type (Diffuse, Nodular, Sclerotic, Adult Cystic, Others), Treatment (Hormone Medications, Anti-Inflammatory Drugs), Patient Type (Adult, Geriatric, Adolescence), Dosage Form (Parenteral, Oral, Others), End User (Hospitals, Clinics, Specialty Centers, Ambulatory Centers, Home Healthcare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) |
|
Countries Covered |
U.S., Canada, and Mexico |
|
Market Players Covered |
Mayne Pharma Group Limited, Accord Healthcare, Tolmar Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, TerSera Therapeutics LLC, Ferring B.V., Lannett, Par Pharmaceutical (A Subsidiary of Endo International plc), Hikma Pharmaceuticals PLC, Context Therapeutics Inc., Viatris Inc., Bayer AG, Teva Pharmaceutical Industries Ltd., AstraZeneca, Pfizer Inc., Zydus Pharmaceuticals, Inc., Sun Pharmaceutical Industries Ltd, AbbVie Inc., Abbott, GlaxoSmithKline plc., Novartis AG, Amneal Pharmaceuticals LLC, Johnson & Johnson Services, Inc., Sanofi, Dr. Reddy's Laboratories Ltd., among others |
Market Definition
Adenomyosis represents a unique pathophysiological condition in which normal-appearing endometrial mucosa resides within the myometrium and is thus protected from menstrual shedding. The resulting ectopic presence of endometrial tissue composed of glands and stroma is thought to affect normal contractile function and peristalsis of uterine smooth muscle, causing menometrorrhagia, infertility, and adverse obstetric outcomes. Adenomyosis imposes a substantial socioeconomic burden from increased medical care and loss of work productivity without mentioning the compromised quality of life.
Adenomyosis has a negative impact on women's quality of life in a high percentage of cases because of abnormal uterine bleeding and pain requiring a lifelong management plan through medical or surgical treatment. The choice depends on the woman's age, reproductive status, and clinical symptoms. However, the disease is increasingly diagnosed in young women with reproductive desire, and conservative treatments are preferred, such as hormonal medications.
North America Adenomyosis Drugs Market Dynamics
Drivers
- High prevalence of adenomyosis disorders
Gynecologic disorders affect the female reproductive system. The most common symptoms of gynecologic disorders include pelvic pain, endometriosis, adenomyosis, abnormal vaginal bleeding, and breast pain and lumps, among others. The significance and severity of these symptoms often depend on age, as these symptoms may be related to hormonal changes that occur with aging.
With the increasing women population worldwide, the target population for female reproductive disorder has also increased. Adenomyosis, a gynecologic condition characterized by the presence of endometrial glands and stroma within the myometrium, can significantly reduce the lifestyle of an individual. Adenomyosis occurs in 8.8% to 61.5% of women undergoing hysterectomy, and rates vary widely by differences in diagnostic criteria and variations between and within pathologists. The prevalence is estimated to range from 20% to 34%, based on patients referred for pelvic imaging rather than the general population of women.
- Advancement in the diagnosis of adenomyosis
The development of imaging techniques, such as MRI and transvaginal ultrasonography (TVUS), has allowed clinicians to make a non-invasive diagnosis of adenomyosis in women also undergoing conservative treatments, identifying different phenotypes of the disease. After some attempts of histological classification, adenomyosis is classified into four subtypes according to MRI lesion localization in the inner or outer myometrium: intrinsic, extrinsic, intramural, and indeterminate.
Opportunity
- Increase demand for disease-specific drug treatment
According to pathogenic mechanisms, several medical hormonal and non-hormonal treatments are used off-label to manage pain and bleeding and to improve fertility outcomes. The use of GnRHa is indicated before fertility treatments to improve the chances of pregnancy in infertile women with adenomyosis, and the highest pregnancy rate is reported in those undergoing frozen embryo transfer after GnRHa pre-treatment. In contrast, the use of GnRHa for pain and bleeding should be considered only for short-term treatment because of menopausal effects. The levonorgestrel-releasing intrauterine system (LNG-IUS) is also an effective, reversible, and long-term treatment used successfully to treat adenomyosis. Results show that it reduces menstrual bleeding, pain, and uterine volume and has an overall satisfaction of 72%. However, new drugs, such as selective progesterone receptor modulators, aromatase inhibitors, valproic acid, and anti-platelet therapy, are under development for the treatment of adenomyosis.
Restraints/Challenges
The diagnostic tests for adenomyosis include highly technologically advanced products. The development of those products involves rigorous research and development by the developing player. Thus, the cost of the product remains high, which proportionally increases the cost of testing. The diagnostic tools and techniques used for the diagnosis of adenomyosis include ovarian endometrioma, adhesions, and deep nodular forms of the disease that often require ultrasonography or magnetic resonance imaging (MRI) to detect. Histologic verification, usually following surgical/laparoscopic visualization, can be useful in confirming the diagnosis, particularly for the most common superficial lesions.
The therapy of adenomyosis involves different stages and different procedures of treatment. Adenomyosis may be treated with surgery, hormonal drugs, anti-inflammatory drugs, etc. The diagnosis of adenomyosis is difficult, and this subsequently results in difficulty in the management of these patients, especially those who are asymptomatic but have a strong desire to preserve their uterus. Herbal drugs and home remedies are used as alternative therapies for the treatment of adenomyosis.
Recent Developments
- In October 2021, Debiopharm, a Swiss-based, Asia-Pacific biopharmaceutical company, and Dexa Medica, a leading Indonesian pharmaceutical company, announced the Indonesian launch of triptorelin for the treatment of women with gynecological disorders, particularly adenomyosis, and its related diseases
- In September 2019, Professor Caroline Gargett and collaborators at the University of Queensland and Monash IVF were awarded a three-year USD 2.07 Million (AUD 3.05 Million) grant to determine the cause of adenomyosis and the physiological processes associated with the diseases
North America Adenomyosis Drugs Market Divide
North America adenomyosis drugs market is categorized into six notable segments which are based on type, treatment, patient type, dosage form, distribution channel, and end user . The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
Type
- Diffuse
- Nodular
- Sclerotic
- Adult cystic
- Others
On the basis of type, the North America adenomyosis drugs market is segmented into diffuse, nodular, sclerotic, adult cystic, and others.
Treatment
- Hormone medications
- Anti-inflammatory drugs
- Others
On the basis of treatment, the North America adenomyosis drugs market is segmented into hormone medications, anti-inflammatory drugs, and others.
Patient Type
- Adolescence
- Adult
- Geriatric
On the basis of patient type, the North America adenomyosis drugs market is segmented into adolescence, adult, and geriatric.
Dosage Form
- Parenteral
- Oral
- Others
On the basis of dosage form, the North America adenomyosis drugs market is segmented into parenteral, oral, and others.
End User
- Hospitals
- Clinics
- Specialty center
- Home healthcare
- Ambulatory centers
- Others
Sur la base de l'utilisateur final, le marché nord-américain des médicaments contre l'adénomyose est segmenté en hôpitaux, cliniques, centres spécialisés, soins de santé à domicile, centres ambulatoires et autres.
Canal de distribution
- Pharmacie hospitalière
- Pharmacie de détail
- Pharmacie en ligne
- Autres
Sur la base du canal de distribution, le marché nord-américain des médicaments contre l'adénomyose est segmenté en pharmacie hospitalière, pharmacie de détail, pharmacie en ligne et autres.
Analyse/perspectives régionales du marché des médicaments contre l'adénomyose en Amérique du Nord
Le marché nord-américain des médicaments contre l’adénomyose est analysé et des informations et tendances sur la taille du marché sont fournies par type, traitement, type de patient, forme posologique, canal de distribution et utilisateur final, comme référencé ci-dessus.
Les régions couvertes par le rapport sur le marché des médicaments contre l’adénomyose en Amérique du Nord sont les États-Unis, le Canada et le Mexique en Amérique du Nord.
Les États-Unis devraient dominer le marché nord-américain des médicaments contre l’adénomyose au cours de la période de prévision en raison d’un grand nombre d’acteurs majeurs du marché.
La section par pays du rapport fournit également des facteurs d'impact sur les marchés individuels et des changements dans la réglementation du marché qui ont un impact sur les tendances actuelles et futures du marché. Des points de données tels que l'analyse de la chaîne de valeur en aval et en amont, les tendances techniques, l'analyse des cinq forces de Porter et les études de cas sont quelques-uns des indicateurs utilisés pour prévoir le scénario de marché pour les différents pays. En outre, la présence et la disponibilité des marques nord-américaines et les défis auxquels elles sont confrontées en raison de la concurrence importante ou rare des marques locales et nationales, l'impact des tarifs nationaux et les routes commerciales sont pris en compte lors de l'analyse prévisionnelle des données nationales.
Analyse du paysage concurrentiel et des parts de marché des médicaments contre l'adénomyose en Amérique du Nord
Le paysage concurrentiel du marché des médicaments contre l'adénomyose en Amérique du Nord fournit des détails sur les concurrents. Les détails inclus sont un aperçu de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence en Amérique du Nord, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit et la domination des applications. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises sur le marché des médicaments contre l'adénomyose en Amérique du Nord.
Français Certains des principaux acteurs du marché sont Mayne Pharma Group Limited, Accord Healthcare, Tolmar Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, TerSera Therapeutics LLC, Ferring BV, Lannett, Par Pharmaceutical (une filiale d'Endo International plc), Hikma Pharmaceuticals PLC, Context Therapeutics Inc., Viatris Inc., Bayer AG, Teva Pharmaceutical Industries Ltd., AstraZeneca, Pfizer Inc., Zydus Pharmaceuticals, Inc., Sun Pharmaceutical Industries Ltd, AbbVie Inc., Abbott, GlaxoSmithKline plc., Novartis AG, Amneal Pharmaceuticals LLC, Johnson & Johnson Services, Inc., Sanofi, Dr. Reddy's Laboratories Ltd., entre autres.
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. Les données du marché sont analysées et estimées à l'aide de modèles statistiques et cohérents du marché. En outre, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. La principale méthodologie de recherche utilisée par l'équipe de recherche DBMR est la triangulation des données, qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). En dehors de cela, les modèles de données comprennent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des parts de marché des entreprises, les normes de mesure et l'analyse des parts de marché entre l'Amérique du Nord et les régions et les fournisseurs. Veuillez demander un appel d'analyste en cas de demande de renseignements supplémentaires.
SKU-
Accédez en ligne au rapport sur le premier cloud mondial de veille économique
- Tableau de bord d'analyse de données interactif
- Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
- Accès d'analyste de recherche pour la personnalisation et les requêtes
- Analyse de la concurrence avec tableau de bord interactif
- Dernières actualités, mises à jour et analyse des tendances
- Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Table des matières
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA ADENOMYOSIS DRUGS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL'S MODEL
4.2 PORTER
5 EPIDEMIOLOGY
6 PIPELINE ANALYSIS FOR ADENOMYOSIS DRUGS MARKET
7 NORTH AMERICA ADENOMYOSIS DRUGS MARKET: REGULATORY SCENARIO
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 HIGH PREVALENCE OF ADENOMYOSIS DISORDERS
8.1.2 INCREASE IN RESEARCH AND DEVELOPMENT OF ADENOMYOSIS DRUG
8.1.3 ADVANCEMENT IN DIAGNOSIS OF ADENOMYOSIS
8.1.4 INCREASING AWARENESS OF ADENOMYOSIS
8.2 RESTRAINTS
8.2.1 HIGH COST OF TESTING AND MEDICATIONS
8.2.2 ADVERSE SIDE-EFFECTS OF ADENOMYOSIS DRUGS
8.3 OPPORTUNITIES
8.3.1 INCREASE DEMAND FOR DISEASE-SPECIFIC DRUG TREATMENT
8.3.2 PARTNERSHIP AND AGREEMENT BY MAJOR PLAYERS
8.3.3 INCREASING SUPPORT OF PRIVATE AND GOVERNMENT AGENCIES FOR TREATMENT
8.4 CHALLENGES
8.4.1 ALTERNATIVE ADENOMYOSIS THERAPIES
8.4.2 IMPROPER DIAGNOSIS OF ADENOMYOSIS
9 NORTH AMERICA ADENOMYOSIS DRUGS MARKET, BY TYPE
9.1 OVERVIEW
9.2 DIFFUSE
9.2.1 BY SYMPTOMS
9.2.1.1 MENORRHAGIA
9.2.1.2 PELVIC PAIN
9.2.1.3 DYSMENORRHEA
9.2.1.4 METRORRHAGIA
9.2.1.5 OTHERS
9.2.2 BY AGE
9.2.2.1 BETWEEN 20 TO 45
9.2.2.2 ABOVE 45
9.2.2.3 BEFORE 20
9.3 NODULAR
9.3.1 BY SYMPTOMS
9.3.1.1 MENORRHAGIA
9.3.1.2 PELVIC PAIN
9.3.1.3 DYSMENORRHEA
9.3.1.4 METRORRHAGIA
9.3.1.5 OTHERS
9.3.2 BY AGE
9.3.2.1 BETWEEN 20 TO 45
9.3.2.2 ABOVE 45
9.3.2.3 BEFORE 20
9.4 SCLEROTIC
9.4.1 BY SYMPTOMS
9.4.1.1 MENORRHAGIA
9.4.1.2 PELVIC PAIN
9.4.1.3 DYSMENORRHEA
9.4.1.4 METRORRHAGIA
9.4.1.5 OTHERS
9.4.2 BY AGE
9.4.2.1 BETWEEN 20 TO 45
9.4.2.2 ABOVE 45
9.4.2.3 BEFORE 20
9.5 ADULT CYSTIC
9.5.1 BY SYMPTOMS
9.5.1.1 MENORRHAGIA
9.5.1.2 PELVIC PAIN
9.5.1.3 DYSMENORRHEA
9.5.1.4 METRORRHAGIA
9.5.1.5 OTHERS
9.5.2 BY AGE
9.5.2.1 BETWEEN 20 TO 45
9.5.2.2 ABOVE 45
9.5.2.3 BEFORE 20
9.6 OTHERS
9.6.1 ATYPICAL POLYPOID ADENOMYOMAS
9.6.1.1 BY SYMPTOMS
9.6.1.1.1 MENORRHAGIA
9.6.1.1.2 PELVIC PAIN
9.6.1.1.3 DYSMENORRHEA
9.6.1.1.4 METRORRHAGIA
9.6.1.1.5 OTHERS
9.6.1.2 BY AGE
9.6.1.2.1 BETWEEN 20 TO 45
9.6.1.2.2 ABOVE 45
9.6.1.2.3 BEFORE 20
9.6.2 JUVENILE CYSTIC ADENOMYOSIS
9.6.2.1 BY SYMPTOMS
9.6.2.1.1 MENORRHAGIA
9.6.2.1.2 PELVIC PAIN
9.6.2.1.3 DYSMENORRHEA
9.6.2.1.4 METRORRHAGIA
9.6.2.1.5 OTHERS
9.6.2.2 BY AGE
9.6.2.2.1 BETWEEN 20 TO 45
9.6.2.2.2 ABOVE 45
9.6.2.2.3 BEFORE 20
10 NORTH AMERICA ADENOMYOSIS DRUGS MARKET, BY TREATMENT
10.1 OVERVIEW
10.2 HORMONE MEDICATIONS
10.2.1 GONADOTROPIN-RELEASING HORMONE ANALOGS (GNRH ANALOGS)
10.2.1.1 LEUPROLIDE ACETATE
10.2.1.2 NAFARELIN
10.2.1.3 GOSERELIN
10.2.1.4 OTHERS
10.2.2 ESTROGEN-PROGESTIN
10.2.2.1 ETHINYL ESTRADIOL (E) + NORETHINDRONE ACETATE (P)
10.2.2.2 CONJUGATED ESTROGENS (E) + MEDROXYPROGESTERONE ACETATE (P)
10.2.2.3 17Β-ESTRADIOL (E) + NORETHINDRONE ACETATE (P)
10.2.2.4 OTHERS
10.2.3 SELECTIVE PROGESTERONE RECEPTOR MODULATORS (SPRMS) OR PROGESTIN
10.2.3.1 LEVONORGESTREL
10.2.3.2 MIFEPRISTONE
10.2.3.3 ASOPRISNIL
10.2.3.4 LONAPRISAN
10.2.3.5 TELAPRISTONE ACETATE
10.2.3.6 ULIPRISTAL ACETATE
10.2.3.7 ONAPRISTONE
10.2.4 AROMATASE INHIBITORS
10.2.4.1 ARIMIDEX
10.2.4.2 FEMARA
10.2.4.3 OTHERS
10.2.5 GONADOTROPIN-RELEASING HORMONE ANTAGONIST
10.2.5.1 ELAGOLIX
10.2.5.2 FIRMAGON
10.2.5.3 OTHERS
10.2.6 SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS)
10.2.6.1 TAMOXIFEN
10.2.6.2 RALOXIFENE
10.2.6.3 BAZEDOXIFENE
10.2.6.4 CLOMIPHENE
10.2.6.5 TOREMIFENE
10.2.6.6 OSPEMIFENE
10.2.6.7 LASOFOXIFENE
10.2.7 ANDROGEN DERIVATIVES
10.2.7.1 DANAZOL
10.2.7.2 GESTRINONE
10.3 ANTI-INFLAMMATORY DRUGS
10.3.1 NON-SELECTIVE NSAIDS
10.3.1.1 IBUPROFEN
10.3.1.2 NAPROXEN
10.3.1.3 DICLOFENAC
10.3.1.4 MEFENAMIC ACID
10.3.1.5 PIROXICAM
10.3.1.6 OTHERS
10.3.2 SELECTIVE COX-2 NSAIDS
10.3.2.1 CELECOXIB
10.3.2.2 VALDECOXIB
10.3.2.3 OTHERS
10.3.3 PREFERENTIAL COX-2 INHIBITORS
10.3.3.1 MELOXICAM
10.3.3.2 ETODOLAC
10.3.3.3 OTHERS
10.4 OTHERS
11 NORTH AMERICA ADENOMYOSIS DRUGS MARKET, BY PATIENT TYPE
11.1 OVERVIEW
11.2 ADULT
11.3 GERIATRIC
11.4 ADOLESCENCE
12 NORTH AMERICA ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM
12.1 OVERVIEW
12.2 ORAL
12.2.1 TABLETS
12.2.2 CAPSULES
12.2.3 SOLUTION
12.2.4 SUSPENSION
12.3 PARENTERAL
12.3.1 INTRAVENOUS
12.3.2 INTRAMUSCULAR
12.4 OTHERS
13 NORTH AMERICA ADENOMYOSIS DRUGS MARKET, BY END USER
13.1 OVERVIEW
13.2 HOSPITAL
13.3 CLINICS
13.4 SPECIALTY CENTER
13.5 HOME HEALTHCARE
13.6 AMBULATORY CENTERS
13.7 OTHERS
14 NORTH AMERICA ADENOMYOSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL
14.1 OVERVIEW
14.2 HOSPITAL PHARMACY
14.3 RETAIL PHARMACY
14.4 ONLINE PHARMACY
14.5 OTHERS
15 NORTH AMERICA ADENOMYOSIS DRUGS MARKET, BY REGION
15.1 NORTH AMERICA
15.1.1 U.S.
15.1.2 CANADA
15.1.3 MEXICO
16 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: COMPANY LANDSCAPE
16.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
17 SWOT ANALYSIS
18 COMPANY PROFILE
18.1 ABBVIE INC.
18.1.1 COMPANY SNAPSHOT
18.1.2 REVENUE ANALYSIS
18.1.3 COMPANY SHARE ANALYSIS
18.1.4 PRODUCT PORTFOLIO
18.1.5 RECENT DEVELOPMENTS
18.1.5.1 ACQUISITION
18.1.5.2 PARTNERSHIP
18.2 PFIZER INC.
18.2.1 COMPANY SNAPSHOT
18.2.2 REVENUE ANALYSIS
18.2.3 COMPANY SHARE ANALYSIS
18.2.4 PRODUCT PORTFOLIO
18.2.5 RECENT DEVELOPMENT
18.2.5.1 MERGER
18.3 SANOFI
18.3.1 COMPANY SNAPSHOT
18.3.2 REVENUE ANALYSIS
18.3.3 COMPANY SHARE ANALYSIS
18.3.4 PRODUCT PORTFOLIO
18.3.5 RECENT DEVELOPMENT
18.3.5.1 MERGER
18.4 TEVA PHARMACEUTICAL INDUSTRIES LTD
18.4.1 COMPANY SNAPSHOT
18.4.2 REVENUE ANALYSIS
18.4.3 COMPANY SHARE ANALYSIS
18.4.4 PRODUCT PORTFOLIO
18.4.5 RECENT DEVELOPMENT
18.4.5.1 PARTNERSHIP
18.5 BAYER AG
18.5.1 COMPANY SNAPSHOT
18.5.2 REVENUE ANALYSIS
18.5.3 COMPANY SHARE ANALYSIS
18.5.4 PRODUCT PORTFOLIO
18.5.5 RECENT DEVELOPMENT
18.5.5.1 ACQUISITION
18.6 ABBOTT
18.6.1 COMPANY SNAPSHOT
18.6.2 REVENUE ANALYSIS
18.6.3 PRODUCT PORTFOLIO
18.6.4 RECENT DEVELOPMENT
18.6.4.1 PRODUCT APPROVAL
18.7 ACCORD HEALTHCARE
18.7.1 COMPANY SNAPSHOT
18.7.2 PRODUCT PORTFOLIO
18.7.3 RECENT DEVELOPMENT
18.8 AMNEAL PHARMACEUTICALS LLC
18.8.1 COMPANY SNAPSHOT
18.8.2 REVENUE ANALYSIS
18.8.3 PRODUCT PORTFOLIO
18.8.4 RECENT DEVELOPMENTS
18.8.4.1 EVENT
18.9 ASTRAZENECA
18.9.1 COMPANY SNAPSHOT
18.9.2 REVENUE ANALYSIS
18.9.3 PRODUCT PORTFOLIO
18.9.4 RECENT DEVELOPMENTS
18.9.4.1 EXPANSION
18.1 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
18.10.1 COMPANY SNAPSHOT
18.10.2 REVENUE ANALYSIS
18.10.3 PRODUCT PORTFOLIO
18.10.4 RECENT DEVELOPMENT
18.11 CONTEXT THERAPEUTICS INC.
18.11.1 COMPANY SNAPSHOT
18.11.2 PRODUCT PORTFOLIO
18.11.3 RECENT DEVELOPMENT
18.11.3.1 EVENT
18.12 DR. REDDY’S LABORATORIES LTD.
18.12.1 COMPANY SNAPSHOT
18.12.2 REVENUE ANALYSIS
18.12.3 PRODUCT PORTFOLIO
18.12.4 RECENT DEVELOPMENT
18.12.4.1 ACQUISITION
18.13 FERRING B.V.
18.13.1 COMPANY SNAPSHOT
18.13.2 PRODUCT PORTFOLIO
18.13.3 RECENT DEVELOPMENTS
18.13.3.1 COLLABORATION
18.14 GLAXOSMITHKLINE PLC
18.14.1 COMPANY SNAPSHOT
18.14.2 REVENUE ANALYSIS
18.14.3 PRODUCT PORTFOLIO
18.14.4 RECENT DEVELOPMENTS
18.14.4.1 PARTNERSHIP
18.15 HIKMA PHARMACEUTICALS PLC
18.15.1 COMPANY SNAPSHOT
18.15.2 REVENUE ANALYSIS
18.15.3 PRODUCT PORTFOLIO
18.15.4 RECENT DEVELOPMENT
18.16 JOHNSON & JOHNSON SERVICES, INC.
18.16.1 COMPANY SNAPSHOT
18.16.2 REVENUE ANALYSIS
18.16.3 PRODUCT PORTFOLIO
18.16.4 RECENT DEVELOPMENT
18.16.4.1 EVENT
18.17 LANNETT
18.17.1 COMPANY SNAPSHOT
18.17.2 REVENUE ANALYSIS
18.17.3 PRODUCT PORTFOLIO
18.17.4 RECENT DEVELOPMENT
18.17.4.1 EVENT
18.18 MAYNE PHARMA GROUP LIMITED
18.18.1 COMPANY SNAPSHOT
18.18.2 REVENUE ANALYSIS
18.18.3 PRODUCT PORTFOLIO
18.18.4 RECENT DEVELOPMENT
18.18.4.1 PRODUCT LAUNCH
18.19 NOVARTIS AG
18.19.1 COMPANY SNAPSHOT
18.19.2 REVENUE ANALYSIS
18.19.3 PRODUCT PORTFOLIO
18.19.4 RECENT DEVELOPMENTS
18.19.4.1 PRODUCT DEVELOPMENT
18.19.4.2 ACQUISITION
18.2 PAR PHARMACEUTICAL ( A SUBSIDIARY OF ENDO INTERNATIONAL PLC)
18.20.1 COMPANY SNAPSHOT
18.20.2 REVENUE ANALYSIS
18.20.3 PRODUCT PORTFOLIO
18.20.4 RECENT DEVELOPMENTS
18.21 SUN PHARMACEUTICAL INDUSTRIES LTD
18.21.1 COMPANY SNAPSHOT
18.21.2 REVENUE ANALYSIS
18.21.3 PRODUCT PORTFOLIO
18.21.4 RECENT DEVELOPMENT
18.22 TERSERA THERAPEUTICS LLC
18.22.1 COMPANY SNAPSHOT
18.22.2 PRODUCT PORTFOLIO
18.22.3 RECENT DEVELOPMENT
18.22.3.1 AGREEMENT
18.23 TOLMAR PHARMACEUTICALS, INC.
18.23.1 COMPANY SNAPSHOT
18.23.2 PRODUCT PORTFOLIO
18.23.3 RECENT DEVELOPMENT
18.23.3.1 PRODUCT LAUNCH
18.23.3.2 EXPANSION
18.24 VIATRIS INC
18.24.1 COMPANY SNAPSHOT
18.24.2 REVENUE ANALYSIS
18.24.3 PRODUCT PORTFOLIO
18.24.4 RECENT DEVELOPMENT
18.24.4.1 AGREEMENT
18.25 ZYDUS PHARMACEUTICALS, INC.
18.25.1 COMPANY SNAPSHOT
18.25.2 PRODUCT PORTFOLIO
18.25.3 RECENT DEVELOPMENTS
18.25.3.1 ACQUISITION
19 QUESTIONNAIRE
20 RELATED REPORTS
Liste des tableaux
TABLE 1 NORTH AMERICA ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 2 NORTH AMERICA DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 3 NORTH AMERICA DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 4 NORTH AMERICA DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 5 NORTH AMERICA NODULAR IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 6 NORTH AMERICA NODULAR IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 7 NORTH AMERICA NODULAR IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 8 NORTH AMERICA SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 9 NORTH AMERICA SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 10 NORTH AMERICA SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 11 NORTH AMERICA ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 12 NORTH AMERICA ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 13 NORTH AMERICA ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 14 NORTH AMERICA OTHERS IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 15 NORTH AMERICA OTHERS IN ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 16 NORTH AMERICA ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 17 NORTH AMERICA ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 18 NORTH AMERICA JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 19 NORTH AMERICA JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 20 NORTH AMERICA ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 21 NORTH AMERICA HORMONE MEDICATION IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 22 NORTH AMERICA HORMONE MEDICATIONS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 23 NORTH AMERICA GONADOTROPIN-RELEASING HORMONE ANALOGS (GNRH ANALOGS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 24 NORTH AMERICA ESTROGEN-PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 25 NORTH AMERICA SELECTIVE PROGESTERONE RECEPTOR MODULATORS (SPRMS) OR PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 26 NORTH AMERICA AROMATASE INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 27 NORTH AMERICA GONADOTROPIN-RELEASING HORMONE ANTAGONIST ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 28 NORTH AMERICA SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 29 NORTH AMERICA ANDROGEN DERIVATIVES IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 30 NORTH AMERICA ANTI-INFLAMMATORY DRUGS IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 31 NORTH AMERICA ANTI-INFLAMMATORY DRUGS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 32 NORTH AMERICA NON-SELECTIVE NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 33 NORTH AMERICA SELECTIVE COX-2 NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 34 NORTH AMERICA PREFERENTIAL COX-2 INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 35 NORTH AMERICA OTHERS IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 36 NORTH AMERICA ADENOMYOSIS DRUGS MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 37 NORTH AMERICA ADULT IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 38 NORTH AMERICA GERIATRIC IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 39 NORTH AMERICA ADOLESCENCE IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 40 NORTH AMERICA ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 41 NORTH AMERICA ORAL IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 42 NORTH AMERICA ORAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 43 NORTH AMERICA PARENTERAL IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 44 NORTH AMERICA PARENTERAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 45 NORTH AMERICA OTHERS IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 46 NORTH AMERICA ADENOMYOSIS DRUGS MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 47 NORTH AMERICA HOSPITAL IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 48 NORTH AMERICA CLINICS IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 49 NORTH AMERICA SPECIALTY CENTER IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 50 NORTH AMERICA HOME HEALTHCARE IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 51 NORTH AMERICA AMBULATORY CENTERS IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 52 NORTH AMERICA OTHERS IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 53 NORTH AMERICA ADENOMYOSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 54 NORTH AMERICA HOSPITAL PHARMACY IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 55 NORTH AMERICA RETAIL PHARMACY IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 56 NORTH AMERICA ONLINE PHARMACY IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 57 NORTH AMERICA OTHERS IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 58 NORTH AMERICA ADENOMYOSIS DRUGS MARKET, BY COUNTRY, 2020-2029 (USD THOUSAND)
TABLE 59 NORTH AMERICA ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 60 NORTH AMERICA DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 61 NORTH AMERICA DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 62 NORTH AMERICA NODULAR IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 63 NORTH AMERICA NODULAR IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 64 NORTH AMERICA SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 65 NORTH AMERICA SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 66 NORTH AMERICA ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 67 NORTH AMERICA ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 68 NORTH AMERICA OTHERS IN ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 69 NORTH AMERICA ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 70 NORTH AMERICA ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 71 NORTH AMERICA JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 72 NORTH AMERICA JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 73 NORTH AMERICA ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 74 NORTH AMERICA HORMONE MEDICATIONS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 75 NORTH AMERICA GONADOTROPIN-RELEASING HORMONE AGONISTS (GNRH AGONISTS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 76 NORTH AMERICA ESTROGEN-PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 77 NORTH AMERICA SELECTIVE PROGESTERONE RECEPTOR MODULATORS (SPRMS) OR PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 78 NORTH AMERICA AROMATASE INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 79 NORTH AMERICA GONADOTROPIN-RELEASING HORMONE ANTAGONIST ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 80 NORTH AMERICA SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 81 NORTH AMERICA ANDROGEN DERIVATIVES IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 82 NORTH AMERICA ANTI-INFLAMMATORY DRUGS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 83 NORTH AMERICA NON-SELECTIVE NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 84 NORTH AMERICA SELECTIVE COX-2 NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 85 NORTH AMERICA PREFERENTIAL COX-2 INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 86 NORTH AMERICA ADENOMYOSIS DRUGS MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 87 NORTH AMERICA ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 88 NORTH AMERICA ORAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 89 NORTH AMERICA PARENTERAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 90 NORTH AMERICA ADENOMYOSIS DRUGS MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 91 NORTH AMERICA ADENOMYOSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 92 U.S. ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 93 U.S. DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 94 U.S. DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 95 U.S. NODULAR IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 96 U.S. NODULAR IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 97 U.S. SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 98 U.S. SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 99 U.S. ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 100 U.S. ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 101 U.S. OTHERS IN ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 102 U.S. ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 103 U.S. ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 104 U.S. JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 105 U.S. JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 106 U.S. ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 107 U.S. HORMONE MEDICATIONS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 108 U.S. GONADOTROPIN-RELEASING HORMONE AGONISTS (GNRH AGONISTS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 109 U.S. ESTROGEN-PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 110 U.S. SELECTIVE PROGESTERONE RECEPTOR MODULATORS (SPRMS) OR PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 111 U.S. AROMATASE INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 112 U.S. GONADOTROPIN-RELEASING HORMONE ANTAGONIST ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 113 U.S. SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 114 U.S. ANDROGEN DERIVATIVES IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 115 U.S. ANTI-INFLAMMATORY DRUGS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 116 U.S. NON-SELECTIVE NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 117 U.S. SELECTIVE COX-2 NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 118 U.S. PREFERENTIAL COX-2 INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 119 U.S. ADENOMYOSIS DRUGS MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 120 U.S. ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 121 U.S. ORAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 122 U.S. PARENTERAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 123 U.S. ADENOMYOSIS DRUGS MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 124 U.S. ADENOMYOSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 125 CANADA ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 126 CANADA DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 127 CANADA DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 128 CANADA NODULAR IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 129 CANADA NODULAR IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 130 CANADA SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 131 CANADA SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 132 CANADA ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 133 CANADA ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 134 CANADA OTHERS IN ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 135 CANADA ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 136 CANADA ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 137 CANADA JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 138 CANADA JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 139 CANADA ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 140 CANADA HORMONE MEDICATIONS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 141 CANADA GONADOTROPIN-RELEASING HORMONE AGONISTS (GNRH AGONISTS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 142 CANADA ESTROGEN-PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 143 CANADA SELECTIVE PROGESTERONE RECEPTOR MODULATORS (SPRMS) OR PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 144 CANADA AROMATASE INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 145 CANADA GONADOTROPIN-RELEASING HORMONE ANTAGONIST ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 146 CANADA SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 147 CANADA ANDROGEN DERIVATIVES IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 148 CANADA ANTI-INFLAMMATORY DRUGS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 149 CANADA NON-SELECTIVE NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 150 CANADA SELECTIVE COX-2 NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 151 CANADA PREFERENTIAL COX-2 INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 152 CANADA ADENOMYOSIS DRUGS MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 153 CANADA ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 154 CANADA ORAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 155 CANADA PARENTERAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 156 CANADA ADENOMYOSIS DRUGS MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 157 CANADA ADENOMYOSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 158 MEXICO ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 159 MEXICO DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 160 MEXICO DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 161 MEXICO NODULAR IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 162 MEXICO NODULAR IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 163 MEXICO SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 164 MEXICO SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 165 MEXICO ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 166 MEXICO ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 167 MEXICO OTHERS IN ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 168 MEXICO ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 169 MEXICO ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 170 MEXICO JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 171 MEXICO JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 172 MEXICO ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 173 MEXICO HORMONE MEDICATIONS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 174 MEXICO GONADOTROPIN-RELEASING HORMONE AGONISTS (GNRH AGONISTS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 175 MEXICO ESTROGEN-PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 176 MEXICO SELECTIVE PROGESTERONE RECEPTOR MODULATORS (SPRMS) OR PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 177 MEXICO AROMATASE INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 178 MEXICO GONADOTROPIN-RELEASING HORMONE ANTAGONIST ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 179 MEXICO SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 180 MEXICO ANDROGEN DERIVATIVES IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 181 MEXICO ANTI-INFLAMMATORY DRUGS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 182 MEXICO NON-SELECTIVE NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 183 MEXICO SELECTIVE COX-2 NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 184 MEXICO PREFERENTIAL COX-2 INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 185 MEXICO ADENOMYOSIS DRUGS MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 186 MEXICO ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 187 MEXICO ORAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 188 MEXICO PARENTERAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 189 MEXICO ADENOMYOSIS DRUGS MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 190 MEXICO ADENOMYOSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
Liste des figures
FIGURE 1 NORTH AMERICA ADENOMYOSIS DRUGS MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA ADENOMYOSIS DRUGS MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA ADENOMYOSIS DRUGS MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA ADENOMYOSIS DRUGS MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA ADENOMYOSIS DRUGS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA ADENOMYOSIS DRUGS MARKET: MULTIVARIATE MODELLING
FIGURE 7 NORTH AMERICA ADENOMYOSIS DRUGS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 NORTH AMERICA ADENOMYOSIS DRUGS MARKET: DBMR MARKET POSITION GRID
FIGURE 9 NORTH AMERICA ADENOMYOSIS DRUGS MARKET: END USER COVERAGE GRID
FIGURE 10 NORTH AMERICA ADENOMYOSIS DRUGS MARKET: VENDOR SHARE ANALYSIS
FIGURE 11 NORTH AMERICA ADENOMYOSIS DRUGS MARKET: SEGMENTATION
FIGURE 12 NORTH AMERICA IS EXPECTED TO DOMINATE AND ASIA-PACIFIC IS GROWING AT THE FASTEST PACE IN NORTH AMERICA ADENOMYOSIS DRUGS MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 13 HIGH PREVALENCE OF ADENOMYOSIS DISORDER AND INCREASE THE RESEARCH AND DEVELOPMENT OF ADENOMYOSIS DRUG ARE DRIVING THE NORTH AMERICA ADENOMYOSIS DRUGS MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 14 DIFFUSE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA ADENOMYOSIS DRUGS MARKET IN 2022 & 2029
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA ADENOMYOSIS DRUGS MARKET
FIGURE 16 NORTH AMERICA ADENOMYOSIS DRUGS MARKET: BY TYPE, 2021
FIGURE 17 NORTH AMERICA ADENOMYOSIS DRUGS MARKET: BY TYPE, 2022-2029 (USD THOUSAND)
FIGURE 18 NORTH AMERICA ADENOMYOSIS DRUGS MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 19 NORTH AMERICA ADENOMYOSIS DRUGS MARKET: BY TYPE, LIFELINE CURVE
FIGURE 20 NORTH AMERICA ADENOMYOSIS DRUGS MARKET: BY TREATMENT, 2021
FIGURE 21 NORTH AMERICA ADENOMYOSIS DRUGS MARKET: BY TREATMENT, 2022-2029 (USD THOUSAND)
FIGURE 22 NORTH AMERICA ADENOMYOSIS DRUGS: BY TREATMENT, CAGR (2022-2029)
FIGURE 23 NORTH AMERICA ADENOMYOSIS DRUGS: BY TREATMENT, LIFELINE CURVE
FIGURE 24 NORTH AMERICA ADENOMYOSIS DRUGS MARKET: BY PATIENT TYPE, 2021
FIGURE 25 NORTH AMERICA ADENOMYOSIS DRUGS MARKET: BY PATIENT TYPE, 2022-2029 (USD THOUSAND)
FIGURE 26 NORTH AMERICA ADENOMYOSIS DRUGS MARKET: BY PATIENT TYPE, CAGR (2022-2029)
FIGURE 27 NORTH AMERICA ADENOMYOSIS DRUGS MARKET: BY PATIENT TYPE, LIFELINE CURVE
FIGURE 28 NORTH AMERICA ADENOMYOSIS DRUGS MARKET: BY DOSAGE FORM, 2021
FIGURE 29 NORTH AMERICA ADENOMYOSIS DRUGS MARKET: BY DOSAGE FORM, 2022-2029 (USD THOUSAND)
FIGURE 30 NORTH AMERICA ADENOMYOSIS DRUGS MARKET: BY DOSAGE FORM, CAGR (2022-2029)
FIGURE 31 NORTH AMERICA ADENOMYOSIS DRUGS MARKET: BY DOSAGE FORM, LIFELINE CURVE
FIGURE 32 NORTH AMERICA ADENOMYOSIS DRUGS MARKET: BY END USER, 2021
FIGURE 33 NORTH AMERICA ADENOMYOSIS DRUGS MARKET: BY END USER, 2022-2029 (USD THOUSAND)
FIGURE 34 NORTH AMERICA ADENOMYOSIS DRUGS MARKET: BY END USER, CAGR (2022-2029)
FIGURE 35 NORTH AMERICA ADENOMYOSIS DRUGS MARKET: BY END USER, LIFELINE CURVE
FIGURE 36 NORTH AMERICA ADENOMYOSIS DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 37 NORTH AMERICA ADENOMYOSIS DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD THOUSAND)
FIGURE 38 NORTH AMERICA ADENOMYOSIS DRUGS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 39 NORTH AMERICA ADENOMYOSIS DRUGS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 40 NORTH AMERICA ADENOMYOSIS DRUGS MARKET: SNAPSHOT (2021)
FIGURE 41 NORTH AMERICA ADENOMYOSIS DRUGS MARKET: BY COUNTRY (2021)
FIGURE 42 NORTH AMERICA ADENOMYOSIS DRUGS MARKET: BY COUNTRY (2022 & 2029)
FIGURE 43 NORTH AMERICA ADENOMYOSIS DRUGS MARKET: BY COUNTRY (2021 & 2029)
FIGURE 44 NORTH AMERICA ADENOMYOSIS DRUGS MARKET: BY TYPE (2022-2029)
FIGURE 45 NORTH AMERICA ADENOMYOSIS DRUGS MARKET: COMPANY SHARE 2021 (%)
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.
La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.
Personnalisation disponible
Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.
